Evolus, Inc. announced that the Aesthetic Surgery Journal has published the safety and duration of effect results from the Phase 2 study of 40U Jeuveau® (prabotulinumtoxinA-xvfs) for the treatment of moderate to severe glabellar lines in adult patients. The " extra-strength" glabellar line study is a multicenter, double-blind, randomized, Phase 2 trial following 150 patients for up to 12 months or until the patient loses their correction. The study has three arms: Jeuveau® Extra- strength 40U and two active controls, BOTOX 20U and Jeuveau 20U.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.75 USD | -2.89% | -4.14% | +21.08% |
05-07 | Evolus, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
05-07 | Transcript : Evolus, Inc., Q1 2024 Earnings Call, May 07, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+21.08% | 798M | |
+30.38% | 684B | |
+26.51% | 568B | |
-4.36% | 361B | |
+19.30% | 329B | |
+3.73% | 284B | |
+16.70% | 240B | |
+8.78% | 208B | |
-7.93% | 200B | |
+7.68% | 166B |
- Stock Market
- Equities
- EOLS Stock
- News Evolus, Inc.
- Evolus, Inc. Announces Publication of Safety and Duration Data from Phase 2 Study for "Extra- Strength" 40U Formulation of Jeuveau